# Exacerbation Study

> **NCT00845728** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3439 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Indacaterol 150 µg
- **DRUG:** Tiotropium

## Key facts

- **NCT ID:** NCT00845728
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 3439 (ACTUAL)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00845728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00845728, "Exacerbation Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00845728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*